YC W23
Invitris
Creating new protein-based drugs at scale
About
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.
Founders
- Patrick Grossmann
- Kilian Vogele
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Invitris.
See family office activityIndustry & Focus
HealthcareDrug Discovery and DeliveryBiotechNanotechnologyDrug discovery